Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2026 16:02 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell...
May 13, 2026 09:24 ET | Source: Research and Markets

Australia Regenerative Medicine Market Research Trends and Forecasts Report 2026-2035 Featuring Prominent Players Such as Abbott Laboratories, Astellas Pharma, and Roche

Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Australia Regenerative Medicine Market - Distribution by Type of Products, Type of Therapeutic Area, End Users and Key Geographical Regions: Industry...
May 13, 2026 09:19 ET | Source: Research and Markets

Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo

Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Japan Regenerative Medicine Market - Distribution by Type of Product, Type of Therapeutic Area, End User and Key Geographical Regions: Industry Trends...
May 12, 2026 08:40 ET | Source: Fortis Life Sciences

Fortis Life Sciences Awards 2026 AbNano® VHH Discovery Grant to Deliver Biosciences for Targeted Drug Delivery Research

Fortis Life Sciences awards Deliver Biosciences the 2026 AbNano® VHH Discovery Grant for in vivo CAR-T, gene therapy & nanoparticle drug delivery research
May 12, 2026 08:00 ET | Source: InVitria

InVitria Presents New Data at ASGCT 2026 on Recombinant Human Serum Albumin for Higher Lentiviral Vector Titers and Improved Cell Therapy Manufacturing

InVitria presents ASGCT 2026 data on recombinant albumin for improved lentiviral vector and cell therapy manufacturing.
May 12, 2026 07:35 ET | Source: MiNK Therapeutics

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic...
May 12, 2026 07:00 ET | Source: https://immatics.com/

Immatics Announces First Quarter 2026 Financial Results and Business Update

SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027Multiple key...
May 11, 2026 08:00 ET | Source: CPTx

CPTx appoints Edward Rebar as Chief Scientific Officer

Strengthening of CPTx executive team with appointment of Edward Rebar, PhD, as Chief Scientific Officer. David Maier is appointed Chief Business Officer.
May 08, 2026 16:05 ET | Source: Longeveron

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron announced that a constructive Type C meeting with the U.S. FDA was held to discuss the ongoing development of laromestrocel in HLHS.
May 06, 2026 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027...